Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.

@article{Nishikawa2015RandomisedPI,
  title={Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.},
  author={Kazuhiro Nishikawa and Kazumasa Fujitani and Hitoshi Inagaki and Yusuke Akamaru and Shinya Tokunaga and Masakazu Takagi and Shigeyuki Tamura and Naotoshi Sugimoto and Tadashi Shigematsu and Takaki Yoshikawa and Tohru Ishiguro and Masato Nakamura and Satoshi Morita and Yumi Miyashita and Akira Tsuburaya and Junichi Sakamoto and Toshimasa Tsujinaka},
  journal={European journal of cancer},
  year={2015},
  volume={51 7},
  pages={808-16}
}
AIM The optimal second-line regimen for treating advanced gastric cancer (AGC) remains unclear. While irinotecan (CPT-11) plus cisplatin (CDDP) combination therapy and CPT-11 monotherapy have been explored in the second-line setting, the superiority of second-line platinum-based therapies for AGC patients initially treated with S-1 monotherapy has not yet been evaluated; therefore, we aimed to examine the survival benefit of CPT-11/CDDP combination over CPT-11 monotherapy. METHODS AGC… CONTINUE READING
Highly Cited
This paper has 131 citations. REVIEW CITATIONS
15 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 15 extracted citations

131 Citations

050100201620172018
Citations per Year
Semantic Scholar estimates that this publication has 131 citations based on the available data.

See our FAQ for additional information.

Similar Papers

Loading similar papers…